TrialBritish journal of cancer2019

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Elodie Maille et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.